Martin Pule
  • Senior Lecturer in Haematology, Haematology University College London
Research focus
  • pathology
  • 2 Author merit

Education

FRCPath, Fellow Royal College of Pathologists , 2021

Publications

https://pubmed.ncbi.nlm.nih.gov/?term=(Pule%2C%20Martin%5BAuthor%5D)%20OR%20(Pule%2C%20Martin%20A%5BAuthor%5D)&sort=pubdate
Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma. Straathof K, Flutter B, Wallace R, Jain N, Loka T, Depani S, Wright G, Thomas S, Cheung GW, Gileadi T, Stafford S, Kokalaki E, Barton J, Marriott C, Rampling D, Ogunbiyi O, Akarca AU, Marafioti T, Inglott S, Gilmour K, Al-Hajj M, Day W, McHugh K, Biassoni L, Sizer N, Barton C, Edwards D, Dragoni I, Silvester J, Dyer K, Traub S, Elson L, Brook S, Westwood N, Robson L, Bedi A, Howe K, Barry A, Duncan C, Barone G, Pule M, Anderson J. Sci Transl Med. 2020 Nov 25;12(571):eabd6169. doi: 10.1126/scitranslmed.abd6169. PMID: 33239386



A primer set for the rapid isolation of scFv fragments against cell surface antigens from immunised rats.

Nannini F, Parekh F, Wawrzyniecka P, Mekkaoui L, Righi M, Dastjerdi FV, Yeung J, Roddie C, Bai Y, Ma B, Ferrari M, Onuoha S, Chester K, Pule M. Sci Rep. 2020 Nov 5;10(1):19168. doi: 10.1038/s41598-020-76069-3. PMID: 33154441



In vivo photoacoustic imaging of a nonfluorescent E2 crimson genetic reporter in mammalian tissues.

Ogunlade O, Stowe C, Jathoul A, Kalber T, Lythgoe M, Beard P, Pule M. J Biomed Opt. 2020 Apr;25(4):1-12. doi: 10.1117/1.JBO.25.4.046004. PMID: 32314561



Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4+ T Cells. Śledzińska A, Vila de Mucha M, Bergerhoff K, Hotblack A, Demane DF, Ghorani E, Akarca AU, Marzolini MAV, Solomon I, Vargas FA, Pule M, Ono M, Seddon B, Kassiotis G, Ariyan CE, Korn T, Marafioti T, Lord GM, Stauss H, Jenner RG, Peggs KS, Quezada SA.

Immunity. 2020 Jan 14;52(1):151-166.e6. doi: 10.1016/j.immuni.2019.12.007. Epub 2020 Jan 7.



Imaging of X-Ray-Excited Emissions from Quantum Dots and Biological Tissue in Whole Mouse.Ryan SG, Butler MN, Adeyemi SS, Kalber T, Patrick PS, Zaw Thin M, Harrison IF, Stuckey DJ, Pule M, Lythgoe MF.

Sci Rep. 2019 Dec 16;9(1):19223. doi: 10.1038/s41598-019-55769-5.

Generation of a neutralizing antibody against RD114-pseudotyped viral vectors. Mekkaoui L, Ferrari M, Mattiuzzo G, Ma B, Nannini F, Onuoha S, Kotsopoulou E, Takeuchi Y, Pule M.J Gen Virol. 2019 Nov 8. doi: 10.1099/jgv.0.001309. [Epub ahead of print]



Near-infrared dual bioluminescence imaging in mouse models of cancer using infraluciferin. Stowe CL, Burley TA, Allan H, Vinci M, Kramer-Marek G, Ciobota DM, Parkinson GN, Southworth TL, Agliardi G, Hotblack A, Lythgoe MF, Branchini BR, Kalber TL, Anderson JC, Pule MA.

Elife. 2019 Oct 15;8. pii: e45801. doi: 10.7554/eLife.45801.



Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Ghorashian S, Kramer AM, Onuoha S, Wright G, Bartram J, Richardson R, Albon SJ, Casanovas-Company J, Castro F, Popova B, Villanueva K, Yeung J, Vetharoy W, Guvenel A, Wawrzyniecka PA, Mekkaoui L, Cheung GW, Pinner D, Chu J, Lucchini G, Silva J, Ciocarlie O, Lazareva A, Inglott S, Gilmour KC, Ahsan G, Ferrari M, Manzoor S, Champion K, Brooks T, Lopes A, Hackshaw A, Farzaneh F, Chiesa R, Rao K, Bonney D, Samarasinghe S, Goulden N, Vora A, Veys P, Hough R, Wynn R, Pule MA, Amrolia PJ. Nat Med. 2019 Sep;25(9):1408-1414. doi: 10.1038/s41591-019-0549-5. Epub 2019 Sep 2.



05/2019 Blood. 2019 May 23;133(21):2246-2247. doi: Anti-CD1a CAR T cells to selectively target T-ALL.

Maciocia PM, Pule MA. (Commentary)



01/2019 Oncoimmunology. 2019 Jan 19;8(4): Transient redirection of T cells for adoptive cell therapy with telomerase-specific T helper cell receptors isolated from long term survivors after cancer vaccination.

Kyte J, Fåne A, Pule M, Gaudernack G.



08/2018 Cancer Discov. 2018 Aug;8(8):918-920. CAR T-cell Integration of Multiple Input Signals Allows for Precise Targeting of Cancer. Achkova D, Pule M. (commentary)



12/2018 Mol Ther Methods Clin Dev. 2018 Oct 23;11:155-165. 2 Lentiviral Vector Purification Using Genetically Encoded Biotin Mimic in Packaging Cell. Mekkaoui L, Parekh F, Kotsopoulou E, Darling D, Dickson G, Cheung GW, Chan L, MacLellan-Gibson K, Mattiuzzo G, Farzaneh F, Takeuchi Y, Pule M.



10/2017 Targeting T-cell receptor β-constant for immunotherapy of T-cell malignancies; Paul M. Maciocia, Patrycja A. Wawrzyniecka, Brian Philip, Ida Ricciardelli, Ayse U. Akarca1, Shimobi Onuoha, Mateusz Legut, David K. Cole, Andrew K. Sewell, Giuseppe Gritti, Joan Somja, Miguel A. Piris, Karl S. Peggs, David C. Linch, Teresa Marafioti, Martin A. Pule. Accepted for Nature Medicine Aug 2017.



01/04/2016 TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors. Menger L, Sledzinska A, Bergerhoff K, Vargas FA, Smith J, Poirot L, Pule, M, Hererro J, Peggs KS, Quezada SA. Cancer Res. 2016 Apr 15;76(8):2087-93. PMID:27197251



31/03/2016 An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers. Thomas S, Straathof K, Himoudi N, Anderson J, Pule M. PLoS One. 2016 Mar 31;11(3):PMID:27030986



04/11/2015 Flow-Based Single Cell Deposition for High-Throughput Screening of Protein Libraries. Stowe C, Pizzey A, Kalber T, Badar A, Lythgoe M, Pule M. PLoS One. 2015 Nov 4;10(11): PMID:26536118

01/11/2015



Deep in vivo photoacoustic imaging of mammalian tissues using a tyrosinase-based genetic reporter. Jathoul A, Laufer J, Ogunlade O, Treeby B, Cox B, Pizzey AR, Lythgoe MF, Pedley RB, Beard P, Pule M. Nature Photonics 9, 239–246(2015) doi:10.1038/nphoton.2015.22



15/09/2015 Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies. Poirot L, Philip B, Schiffer-Mannioui C, Le Clerre D, Chion-Sotinel I, Derniame S, Potrel P, Bas C, Lemaire L, Galetto R, Lebuhotel C, Eyquem J, Cheung GW, Duclert A, Gouble A, Arnould S, Peggs K, Pule M, Scharenberg AM, Smith J. Cancer Res. 2015 Sep 15;75(18):3853-64. PMID:26183927



21/08/2014 A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Philip B, Kokalaki E, Mekkaoui L, Thomas S, Straathof K, Flutter B, Marin V, Marafioti T, Chakraverty R, Linch D, Quezada SA, Peggs KS, Pule M. Blood. 2014 Aug 21;124(8):1277-87. PMID:24970931



23/12/2012 Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. Marin V, Cribioli E, Philip B, Tettamanti S, Pizzitola I, Biondi A, Biagi E, Pule M. Hum Gene Ther Methods. 2012 Dec;23(6):376-86. PMID:23186165



26/11/2009 Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease. Brewin J, Mancao C, Straathof K, Karlsson H, Samarasinghe S, Amrolia PJ, Pule M. Blood. 2009 Nov 26;114(23):4792-803. PMID:19770360



01/11/2008 Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK. Nat Med. 2008 Nov;14(11):1264-70. PMID:18978797



12/11/2005 A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Pulè MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK. Mol Ther. 2005 Nov;12(5):933-41. PMID:15979412

2 Protocols published
SARS-CoV-2刺突慢病毒伪型载体制备和滴定的优化方法

The use of recombinant lentivirus pseudotyped with the coronavirus Spike protein of SARS-CoV-2 would circumvent the requirement of biosafety-level 3 (BSL-3) containment facilities for the handling of SARS-CoV-2 viruses. Herein, we describe a fast

...
SARS-CoV-2假型慢病毒载体制备及滴定方法的优化

The use of recombinant lentivirus pseudotyped with the coronavirus Spike protein of SARS-CoV-2 would circumvent the requirement of biosafety-level 3 (BSL-3) containment facilities for the handling of SARS-CoV-2 viruses. Herein, we describe a fast

...
We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.